LENZ Therapeutics (LENZ) Stock Price, News & Analysis

Company Overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Key Stats

• Today's Range: $45.20 to $47.10
• 50-Day Range: $29.33 to $49.05
• 52-Week Range: $16.53 to $50.40
• Volume: 269,880 shs
• Average Volume: 320,362 shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.60
• Consensus Rating: Moderate Buy

LENZ Therapeutics Stock Analysis - MarketRank™

LENZ Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 870th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for LENZ Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

LENZ Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LENZ Therapeutics is -24.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENZ Therapeutics is -24.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENZ Therapeutics has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.88% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in LENZ Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENZ Therapeutics does not currently pay a dividend.

Dividend Growth

LENZ Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

20.88% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in LENZ Therapeutics has recently increased by 1.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.57

News Sentiment

LENZ Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

10 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of LENZ Therapeutics is held by insiders.

Percentage Held by Institutions

54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LENZ Stock Analysis - Frequently Asked Questions

How have LENZ shares performed this year?

LENZ Therapeutics' stock was trading at $28.87 at the beginning of the year. Since then, LENZ stock has increased by 58.2% and is now trading at $45.6610.

How were LENZ Therapeutics' earnings last quarter?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) issued its earnings results on Wednesday, July, 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5 million for the quarter, compared to analysts' expectations of $5 million.

How do I buy shares of LENZ Therapeutics?

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LENZ Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LENZ
• Previous Symbol: NASDAQ:LENZ
• CIK: 1815776
• Web: www.graphitebio.com
• Phone: 650-484-0886
• Fax: N/A
• Employees: 110
• Year Founded: 2013

Price Target and Rating

• Average Price Target for LENZ Therapeutics: $49.60
• High Price Target: $60.00
• Low Price Target: $40.00
• Potential Upside/Downside: +7.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.77 million
• Net Margins: N/A
• Pretax Margin: -1,037.94%
• Return on Equity: -25.63%
• Return on Assets: -24.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.54
• Quick Ratio: 20.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.42 per share
• Price / Book: 6.22

Miscellaneous

• Outstanding Shares: 28,520,000
• Free Float: 26,554,000
• Market Cap: $1.32 billion
• Optionable: N/A
• Beta: 0.50